on all orders above $300.00

FREE Pills!

via4gra pills

for free with every order



Less than in your
local pharmacy

Search by letter:

Combutol (Myambutol)

Rating of sales:          


Combutol (generic name: ethambutol; brand names include: EMB / Etibi / Combutol / Mycobutol / Tibitol / Servambutol / Tibinil) belongs to a group of medicines called antitubercular agents. Combutol is used for the treatment of pulmonary tuberculosis, usually in combination with other antituberculosis medicines.

Other names for this medication:
Etambutol, Ethambutol, Myambutol, Rifafour, Rimstar

Similar Products:
Moxifloxacin, Streptomycin, Etibi, Rifadin, Rofact, Levaquin, Avelox, Mycobutin


Also known as:  Myambutol.


Combutol is a prescription medication used to treat tuberculosis (TB). Combutol belongs to a group of drugs called antimycobacterial antibiotics. TB is caused by a certain bacteria. Combutol works by stopping the bacteria from forming a cell wall, which kills the bacteria.

This medication comes in tablet form. It is taken once a day with or without food.

Common side effects of Combutol include loss of appetite, upset stomach, and numbness or tingling in hands and feet.


Combutol should not be used alone, in initial treatment or in retreatment. Combutol should be administered on a once every 24-hour basis only. Absorption is not significantly altered by administration with food. Therapy, in general, should be continued until bacteriological conversion has become permanent and maximal clinical improvement has occurred.

Combutol is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.


If you take too much Combutol, call your local Poison Control Center or seek emergency medical attention right away.


Store at room temperature between 20 and 25 degrees C (68 and 77 degrees F) away from moisture and heat. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Side effects

The most common side effects associated with Combutol are:

  • combutol dose
  • combutol 800 tablet uses
  • combutol 400 mg
  • combutol tablet uses
  • combutol 1000 mg side effects
  • combutol syrup
  • tab combutol
  • combutol 800 dosage
  • combutol 600 mg
  • tab combutol 600
  • combutol 200 mg
  • combutol drug
  • combutol 1200 mg
  • tab combutol 800
  • overdose of combutol
  • combutol 800 mg side effects
  • combutol 800 medicine
  • combutol 800 mg
  • combutol 800 tablet
  • tablet combutol 600
  • tab combutol 800 mg
  • tablet combutol 800 mg
  • combutol tablet side effects
  • combutol 1000 mg uses
  • tab combutol 1000
  • combutol 400 mg tab
  • combutol tablet
  • dose of combutol
  • tab combutol 1gm
  • combutol generic name
  • combutol 600 mg side effects
  • combutol tab
  • combutol medicine
  • combutol dosage
  • use of combutol 800 tablet
  • tablet combutol 1000
  • combutol 600 dosage
  • combutol 1200 mg side effects
  • combutol 1000 mg price
  • combutol 800 tablet side effects
  • tab combutol uses

Side effect occurrence does not only depend on medication you are taking, but also on your overall health and other factors.


Do not take Combutol if you are allergic to any of its ingredients.

Because this medication may have adverse effects on vision, talk to your doctor if you have eye problems such as optic neuritis, cataracts, or diabetic retinopathy.

Tell your doctor if you have kidney disease as your doctor may need to decrease the dose you take.

combutol tablet uses

RNFL thickness associated with ethambutol optic neuropathy during the early stages was no different from the controls. Although not statistically significant, the relative thickening of temporal RNFL in our patients might represent a mild swelling of the papillomacular bundle.

combutol dose

Entrapment efficiency of ethambutol hydrochloride ranged from 12.20% to 25.81%. Zeta potential values inferred stability of neutral and negatively charged formulations. In vitro release was biphasic. Lung targeting was increased by niosomal encapsulation. Biological evaluation revealed superiority of niosomal ethambutol hydrochloride over the free drug.

tab combutol 1000

Our results indicated that M. abscessus infection developed during the treatment for non-abscessus mycobacterial disease, which was mainly due to M. avium complex pulmonary disease in most patients. M. abscessus infection thus occurred via microbial substitution. This phenomenon should be considered an important issue during the treatment for non-abscessus mycobacterial disease, which requires long-term medication.

tab combutol 600

The authors describe radiologic findings of cystic lung disease associated with pulmonary tuberculosis.

combutol 200 mg

Of 260 Mycobacterium tuberculosis isolates, 41 (15.8%) were resistant to at least one first-line drug, 13 (5.0%) were multidrug-resistant (MDR) and 9 (3.5%) were resistant to all first-line drugs. Any resistance to INH, RMP, SM, EMB and PZA was respectively 36 (13.8%), 15 (5.8%), 26 (10.0%), 19 (7.3%) and 12 (4.6%). Of 214 new and 46 previously treated cases, respectively 8 (3.7%) and 5 (10.9%) were MDR. All isolates were susceptible to all second-line drugs.

tab combutol uses

These results suggest that the actual heterogeneity of the bacillary population in patients, especially in high TB incidence settings, may be frequently underestimated using current analytical schemes. These findings have therefore important implications for correct interpretation and evaluation of molecular epidemiology data and in treatment evaluations.

overdose of combutol

We present here the first report of disseminated skin Mycobacterium infections in two liver transplant recipients, in which hsp65 gene sequencing was used for rapid species identification. Both patients had hepatitis B virus-related cirrhosis and diabetes mellitus and presented with progressive generalized, nodular skin lesions. In one patient, a 50-year-old woman who had frequent contact with marine fish, an acid-fast bacillus was isolated from skin biopsy tissue after 2 months of culture. While awaiting phenotypic identification results, hsp65 gene sequencing showed that it was most closely related to that of Mycobacterium marinum with 100% nucleotide identity. The patient was treated with oral rifampin, ethambutol, and moxifloxacin. In the other patient, a 59-year-old woman, direct PCR for Mycobacterium using hsp65 gene from skin biopsy tissue was positive, with the sequence most closely related to that of M. haemophilum with 100% nucleotide identity. Based on PCR results, the patient was treated with clarithromycin, ethambutol, moxifloxacin, and amikacin. A strain of M. haemophilum was only isolated after 3 months. Skin lesions of both patients resolved after 1 year of antimycobacterial therapy. Nontuberculous Mycobacterium infections should be considered in liver transplant recipients presenting with chronic, nodular skin lesions. This report highlights the crucial role of hsp65 gene PCR and sequencing on both cultured isolates and direct clinical specimens for rapid diagnosis of slow-growing Mycobacterium infection.

combutol 600 mg

The rifampicin and isoniazid resistance rates were much higher than those in the adult TB population in India.

Target Point Shipping Method Tracking Delivery Time Price
Worldwide shipping

Worldwide shipping

Registered Mail  Not trackable 14-21 business days USD 20.00 per order
EMS  Trackable, where available 5-9 business days USD 30.00 per order

Delivery time is:

Registered Mail - 14-21 business days, prices - USD 20.00, no signature is required on delivery.
EMS - 5-9 business days, prices - USD 30.00, signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.

front back side

This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).

 Show Hide 
tablet combutol 600 2017-07-17

The thirty-two times of treatment in 27 patients with multidrug-resistant tuberculosis (MDR-TB) were analyzed retrospectively. In twenty-eight times of treatments cases had previous histories of antituberculosis chemotherapy. Drug sensitivity tests were performed by Microtiter method for isoniazid (INH), rifampicin (RFP), ethambutol, streptomycin, kanamycin, enviomycin, ethionamide, para-aminosalicylic acid and cycloserine. A drug is defined as 'active drug' when the drug was proved to be sensitive by the drug sensitivity tests or never used in the past or used for not more than 2 months in case of pyrazinamide (PZA) and less than one month for fluoroquinolones. Outcomes of Clavaseptin 250 Mg Palatable Tablets treatments were grouped as follows; A: bacteriologically negative for more than 24 months, B: bacteriologically negative for more than 6 months but less than 24 months, C: bacteriologically relapsed after negative conversion, D: continuously bacilli positive for M. tuberculosis. Mean age of patients in each group were; 61.0 yrs for group A (n = 10), 61.0 yrs for group B (n = 7), 52.5 yrs for group C (n = 4), 57.9 yrs for group D (n = 11). All patients had cavitary disease and positive sputum smears for acid-fast bacilli. Mean numbers of 'active drugs' used per treatment in each group, were 3.6, 3.3, 2.5 and 1.8 respectively, while the mean number of resistant drug including INH and RFP were 2.8, 3.3, 2.5 and 3.7. The number of drugs, which was unable to use due to toxicity, were 0.20, 0.14, 0.50, and 0.73 per treatment respectively. All of 9 patients treated with four 'active drugs' were in group A or B and succeeded to achieve negative conversion. The duration of chemotherapy in group A was 13 to 44 months. Treatment had failed in 4 out of 11 patients treated with 3 'active drugs' and 11 out of 12 patients treated with less than 2 'active drugs'. Fluoroquinolones (ofloxacin, levofloxacin or sparfloxacin) were used in 7 out of 10 patients in group A and in 6 out of 9 patients treated with four-drug regimens while they were used only in 3 out of 11 patients in group D. Regimens with at least 4 sensitive drugs are mandatory for the successful treatment of MDR-TB and fluoroquinolones are needed in the majority of cases to ensure the four-drug regimen, because of frequent drug resistance or toxicity to other antituberculosis drugs.

dose of combutol 2016-01-01

Efavirenz is commonly used to treat patients coinfected with human immunodeficiency virus and tuberculosis. Previous clinical studies have observed paradoxically elevated efavirenz plasma concentrations in patients with the CYP2B6*6/*6 genotype (but not the CYP2B6*1/*1 genotype) during coadministration with the commonly used four-drug antituberculosis therapy. This study sought to elucidate the mechanism underlying this genotype-dependent drug-drug interaction. In vitro studies were conducted to determine whether one or more of the antituberculosis drugs (rifampin, isoniazid, pyrazinamide, or ethambutol) potently inhibit efavirenz 8-hydroxylation by CYP2B6 or efavirenz 7-hydroxylation by CYP2A6, the main mechanisms of efavirenz clearance. Time- and concentration-dependent kinetics of inhibition by the antituberculosis drugs were determined using genotyped human liver microsomes (HLMs) and recombinant CYP2A6, CYP2B6.1, and CYP2B6.6 enzymes. Although none of the antituberculosis drugs evaluated at up to 10 times clinical plasma concentrations were found to inhibit efavirenz 8-hydroxylation by HLMs, both rifampin (apparent inhibition constant [Ki] = 368 μM) and pyrazinamide (Ki = Levoflox Brand Name 637 μM) showed relatively weak inhibition of efavirenz 7-hydroxylation. Importantly, isoniazid demonstrated potent time-dependent inhibition of efavirenz 7-hydroxylation in both HLMs (inhibitor concentration required for half-maximal inactivation [KI] = 30 μM; maximal rate constant of inactivation [kinact] = 0.023 min(-1)) and recombinant CYP2A6 (KI = 15 μM; kinact = 0.024 min(-1)) and also formed a metabolite intermediate complex consistent with mechanism-based inhibition. Selective inhibition of the CYP2B6.6 allozyme could not be demonstrated for any of the antituberculosis drugs using either recombinant enzymes or CYP2B6*6 genotype HLMs. In conclusion, the results of this study identify isoniazid as the most likely perpetrator of this clinically important drug-drug interaction through mechanism-based inactivation of CYP2A6.

tablet combutol 1000 2017-01-25

Abstract A 27-year-old man admitted for high fever, wet cough and abnormality on his chest radiograph. He was diagnosed as pulmonary tuberculosis, and started treatment with INH, RFP, EB, and PZA. After other examinations, he was diagnosed as having a acquired immunodeficiency syndrome, too. We gave him zidovudine and lamivudine/ abacavir sulfate to treat HIV infection. After starting treatment with anti-tuberculosis drugs his fever alleviated, but after 10 days from the start of anti-HIV drugs, he showed high fever, and abnormality of his chest radiograph exacervated. We diagnosed him as immune Cefdinir To Treat Sinus Infection reconstitution syndrome, and gave him prednisolone 30 mg/day. His symptoms improved gradually.

combutol 800 dosage 2017-11-12

To study the epidemiology of resistant tuberculosis (TB Ciproxin Dose In Renal Failure ).

combutol 400 mg tab 2017-09-17

A retrospective analysis of 434 patients with vertebral tuberculosis who were treated surgically was performed with special reference to the preoperative duration of chemotherapy. Of these, 376 underwent 4 weeks of a chemotherapy regimen with isoniazid, rifampin and ethamburol, and in 2 re-activation of the disease was observed. The remaining 58 underwent operation for neurological impairment with 6-18 h of the same chemotherapy regimen, and in no case did re-activation occur. These results suggest a shorter duration of chemotherapy may be utilised in all Cefpodoxime Proxetil Tablets Side Effects patients undergoing surgical treatment for vertebral tuberculosis, providing a thorough debridement is performed, leaving no necrotic or infected tissue behind.

combutol 600 mg side effects 2017-08-14

Tuberculosis is a chronic bacterial infection caused by Mycobacterium tuberculosis. It continues as an important cause of morbidity and mortality worldwide, especially in impoverished countries and where human immunodeficiency virus infection is endemic. The modern treatment of tuberculosis is based on the administration of effective drugs. Regimens do not differ for pulmonary and extra-pulmonary tuberculosis. In order to prevent the emergence of drug-resistant organisms, which is present initially in very small numbers, at least two effective drugs are always required. Short-course therapy has been developed to mitigate the consequences of patient default. It is best considered as consisting of two phases. An initial 2-month intensive phase of daily therapy should include isoniazid, rifampin, ethambutol and pyrazinamide. A consolidation phase of daily therapy with isoniazid and rifampin should be continued for an additional 4 months, preferably more for special clinical circumstances. This standardized drug strategy is successful only if the resources conserved by shortening treatment are used to maintain patient compliance. Completely supervised regimens have been also developed with success. Defaults lead not only to treatment failure but also the emergence Milixim 200 Tablet Price and transmission of drug-resistant organisms. Treatment of confirmed or suspected drug-resistant tuberculosis is difficult and should only be made on experts consultation. More difficult to use and/or less effective than first line drugs, second line drugs could be chosen and associated. However drug toxicities should be monitored, with greatest concern to hepatitis. Follow-up of patients must be organised until 2 years after the completion of therapy to detect relapses. Treatment includes prophylactic measures which are a major modality for decreasing the spread of infection.